1 August 2018Americas

Amneal obtains non-infringement finding in Sensipar case

Generic drug maker Amneal has secured a finding of non-infringement in a Hatch-Waxman case over kidney disease drug Sensipar (cinacalcet hydrochloride).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Amgen takes on Emcure over Sensipar generic

10 September 2018 Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.

Court grants order to resolve Amgen v FDA paediatric dispute

6 June 2017 A district court has granted a stipulated order to the US Food and Drug Administration and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar.

Amgen sues Apotex over Sensipar generic

14 October 2016 Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar tablets.

More on this story

Amgen takes on Emcure over Sensipar generic

10 September 2018 Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.

Court grants order to resolve Amgen v FDA paediatric dispute

6 June 2017 A district court has granted a stipulated order to the US Food and Drug Administration and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar.

Amgen sues Apotex over Sensipar generic

14 October 2016 Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar tablets.

More on this story

Amgen takes on Emcure over Sensipar generic

10 September 2018 Amgen has accused India-based Emcure Pharmaceuticals of patent infringement, in a bid to protect its drug Sensipar.

Court grants order to resolve Amgen v FDA paediatric dispute

6 June 2017 A district court has granted a stipulated order to the US Food and Drug Administration and Amgen, after they jointly asked the court to end a case centring on paediatric exclusivity for Sensipar.

Amgen sues Apotex over Sensipar generic

14 October 2016 Amgen has filed a complaint against Apotex for allegedly infringing a patent centring on Sensipar tablets.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC

UKIPO rejects Boehringer’s SPC for horse inhaler